

by reducing the pain and ease of delivery associated with ITDT. However, as modernization in intrathecal drug delivery limits the area of research due to cost of therapy, requirement of trained personal for administration of medicine and pain associated with route. Although nanotechnology has helped to overcome such barrier, the safety and efficacy regarding this technology will be resolved in the near future.

REFERENCES

- [1] L. Lynch, Intrathecal drug delivery systems, *Continuing Educ. Anaesth. Critic. Care Pain* 14 (1) (2014) 27–31.
- [2] C. Maria, J. Hamann, C. Tsai, H. Tator, M. Shoichet, Novel intrathecal delivery system for treatment of spinal cord injury, *Exp. Neurol.* 182 (2) (2003) 300–309.
- [3] N. Vykhotseva, N. McDannold, K. Hynynen, Progress and problems in the application of focused ultrasound for blood–brain barrier disruption, *Ultrasonics* 48 (4) (2008) 279–296.
- [4] P. Bhatt, P. Narvekar, Challenges and strategies for drug transport across the blood brain barrier, *ARC J. Neurosci.* 3 (3) (2018) 17–21.
- [5] L.A. Bors, F. Erdöl, Overcoming the blood–brain barrier. Challenges and tricks for CNS drug delivery, *Sci. Pharm.* 87 (1) (2019) 6.
- [6] M.-A. Bellavance, M. Blanchette, D. Fortin, Recent advances in blood–brain barrier disruption as a CNS delivery strategy, *AAPS J.* 10 (1) (2008) 166–177.
- [7] J.L. Mikitsh, A.-M. Chacko, Pathways for small molecule delivery to the central nervous system across the blood–brain barrier, *Perspect. Med. Chem.* (2014) S13384.
- [8] S.I. Rapoport, M. Hori, I. Klatzo, Testing of a hypothesis for osmotic opening of the blood–brain barrier, *Am. J. Physiol.* 223 (2) (1972) 323–331.
- [9] P.D. Leeson, A.M. Davis, Time-related differences in the physical property profiles of oral drugs, *J. Med. Chem.* 47 (25) (2004) 6338–6348.
- [10] J. Rip, Liposome technologies and drug delivery to the CNS, *Drug Discov. Today Technol.* 20 (2016) 53–58.
- [11] G.T. Noble, J.F. Stefanick, J.D. Ashley, T. Kiziltepe, B. Bilgicir, Ligand-targeted liposome design: challenges and fundamental considerations, *Trends Biotechnol.* 32 (1) (2014) 32–45.
- [12] S. Kabu, Y. Gao, B.K. Kwon, V. Labhasetwar, Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury, *J. Control. Release* 219 (10) (2015) 141–154.
- [13] M.J. Serramia, S. Alvarez, E.F. Paniagua, M.I. Clemente, S.J. Nieves, R. Gomez, J. Mata, M. Fernandez, In vivo delivery of siRNA to the brain by carbosilane dendrimer, *J. Control. Release* 28 (200) (2015) 60–70.
- [14] R.Q. Huang, Y.H. Qu, W.L. Ke, J.H. Zhu, Y.H. Pei, C. Jiang, Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer, *FASEB J.* 21 (4) (2007) 1117–1125.
- [15] A. Papagiannaros, K. Dimas, G. Papaioannou, C. Demetzos, Doxorubicin–PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines, *Int. J. Pharm.* 302 (1–2) (2005) 29–38.
- [16] E. Ghasemian, A. Vatanara, N. Navidi, M.R. Rouini, Brain delivery of baclofen as a hydrophilic drug by nanolipid carriers: characteristics and pharmacokinetics evaluation, *Drug Delivery Sci. Technol.* 37 (2016) 67–73.
- [17] G.J. Grant, B. Piskoun, M. Bansinth, Intrathecal administration of liposomal neostigmine prolongs analgesia in mice, *Acta Anaesthesiol. Scand.* 46 (1) (2002) 90–94.
- [18] G.H. Rodrigues da Silva, L.N.M. Ribeiro, H. Mitsutake, V. A. Guilherme, S.R. Castro, R.J. Poppi, C. Marcia, E. Paula, Optimised NLC: a nanotechnological approach to improve the anaesthetic effect of bupivacaine, *Int. J. Pharm.* 529 (1–2) (2017) 253–263.
- [19] E.A. Nance, G.F. Woodworth, K.A. Sailor, T. Y. Shih, Q. Xu, G. Swaminathan, D. Xiang, C. Eberhart, J.A. Hanes, Dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue, *Nanomedicine* 4 (149) (2012) 2–9.
- [20] J. Shin, Y. Yin, D.K. Kim, S.Y. Lee, W. Lee, J. W. Kang, J. Hong, Foxp3 plasmid-encapsulated PLGA nanoparticles attenuate pain behavior in rats with spinal nerve ligation, *Nanomedicine* 18 (2019) 90–100.
- [21] M. Azizi, F. Farahmandghavi, M. Taghi Joghataei, M. Zandi, M. Imani, M. Bakhtiari, H. Omidian, ChABC-loaded PLGA nanoparticles: a comprehensive study on biocompatibility, functional recovery, and axonal regeneration in animal model of spinal cord injury, *Int. J. Pharm.* 15 (577) (2020) 119037.
- [22] P.C. Wu, D.B. Shieh, H.T. Hsiao, J.C.F. Wang, Y.C. Lin, Y.C. Liu, Magnetic field distribution modulation of intrathecal delivered ketorolac iron-oxide nanoparticle conjugates produce excellent analgesia for chronic inflammatory pain, *J. Nanobiotechnol.* 16 (1) (2018) 49.
- [23] H. Marie, L. Lemaire, F. Franconi, S. Lajnef, Y. M. Frapart, V. Nicolas, S. Lesieur, Superparamagnetic liposomes for MRI monitoring and external magnetic field-induced selective targeting of malignant brain tumors, *Adv. Funct. Mater.* 25 (8) (2015) 1258–1269.
- [24] A.J. Cole, A.E. David, J. Wang, C.J. Galbán, V. C. Yang, Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles, *Biomaterials* 32 (26) (2011) 6291–6301.
- [25] D.G. Carter, Z.Y. Ong, M.C. McGilvery, L.E. Dunlop, D. T. Dexter, A.E. Porter, *l*-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted nanovehicles, *Nanomedicine* 15 (1) (2019) 1–11.
- [26] R. Prades, S. Guerrero, E. Araya, C. Molina, E. Salas, E. Zurita, J. Selva, G. Egea, C. López-Iglesias, M. Teixidó, K. Mj, E. Giral, Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor, *Biomaterials* 33 (29) (2012) 7194–7205.